Breast Cancer

Fulvestrant is a hormonal therapy that targets the estrogen receptor and helps slow cancer growth.

Faslodex reduced disease progression by 20% among women with HR+, HER2- advanced breast cancer.

Hormone therapy is recommended to treat menopause symptoms, but is not recommended for breast cancer survivors.

Women who worked the night shift found to have a greater risk of developing breast cancer.

Breast cancer treatment may cause women to enter menopause prematurely.

A first-in-class selective retinoic acid receptor alpha agonist is being tested in phase 2 clinical trials for acute myeloid leukemia and myelodysplastic syndrome.

T cell responses in different tumor models are fundamentally similar.

A first-in-class molecule was found to inhibit primary and recurrent breast cancer.

Carolyn Choate journeys 300 miles in a kayak to honor the pharmacologist who created the lifesaving aromatase inhibitor.

Top news of the week from Specialty Pharmacy Times.

The new compounds may lead to a highly effective, next-line treatment for estrogen receptor-positive breast cancer.

In some cases, chemotherapy can spur cancer cells to spread to other parts of the body.

Paclitaxel chemotherapy may turn on a stress gene that allows cancer cells to escape from the primary tumor.

The receptor helps drive estrogen-receptor positive mammary tumor progression in low estrogen environments.

Understanding why some patients fail to respond to immunotherapy could improve treatments for cancer.

Young black women are more likely to have aggress breast cancer subtypes than white women.

Targeted radiotherapy for breast cancer may improve overall quality of life and reduces side effects.

Studying HER2-positive breast cancer at the cellular level may yield new treatments.

Brandon Shank, PharmD, MPH, BCOP, discusses the role of the oncology pharmacist in providing consultation and maintaining communication with cancer patients during treatment.

Three weeks of radiation post-mastectomy observed to be safe and effective for breast cancer patients.

Rising breast cancer rates in Japan highlights the need for clinical trials that include this population.

Nearly 1 million cancer deaths in China were the result of exposure to modifiable risk factors.

Discovery may lead to new immunotherapies for aggressive breast cancer.

Top articles of the week from Specialty Pharmacy Times.

Investigators compare long-term overall and disease-free survival rates in neoadjuvant versus adjuvant radiotherapy.